Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells

10Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Suberoyl bis-hydroxamic acid (SBHA) is a histone deacetylase inhibitor that has shown anticancer activity against numerous types of human cancer. The aim of the current study was to explore the effects of SBHA on the proliferation and apoptosis of breast cancer cells. MCF-7 breast cancer cells were treated with different concentrations of SBHA and tested for cell viability, apoptosis and gene expression changes. The results showed that SBHA significantly inhibited the proliferation of MCF-7 cells in a concentration-dependent manner, as determined using a Cell Counting kit-8 assay. SBHA-treated MCF-7 cells showed G0/G1 cell-cycle arrest, coupled with elevated expression levels of p21 and p27 proteins. Hoechst 33258 staining revealed cell shrinkage, chromosomal condensation and nuclear fragmentation in MCF-7 cells treated with SBHA. Flow cytometric analysis of Annexin V-stained cells showed that SBHA treatment induced apoptotic cell death in a concentration-dependent manner. Western blot analysis confirmed the upregulation of Bax and the downregulation of Bcl-2 by SBHA. In conclusion, these results indicate that SBHA exerts cytotoxic effects against human breast cancer cells, which involves the modulation of p21, p27 and Bcl-2 family proteins, consequently leading to cell-cycle arrest and apoptosis.

References Powered by Scopus

The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality

587Citations
N/AReaders
Get full text

HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications

400Citations
N/AReaders
Get full text

BCL-2 family proteins: Critical checkpoints of apoptotic cell death

379Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Toward Multi-Targeted Platinum and Ruthenium Drugs - A New Paradigm in Cancer Drug Treatment Regimens?

516Citations
N/AReaders
Get full text

Histone deacetylase inhibitors: An attractive therapeutic strategy against breast cancer

164Citations
N/AReaders
Get full text

Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action

72Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Yang, X., Zhang, N., Shi, Z., Yang, Z., & Hu, X. (2015). Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells. Molecular Medicine Reports, 11(4), 2908–2912. https://doi.org/10.3892/mmr.2014.3076

Readers over time

‘14‘16‘17‘18‘19‘20‘23‘2400.751.52.253

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

56%

Researcher 3

33%

Lecturer / Post doc 1

11%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 2

29%

Psychology 2

29%

Biochemistry, Genetics and Molecular Bi... 2

29%

Chemistry 1

14%

Save time finding and organizing research with Mendeley

Sign up for free
0